Study of the effects of interferon β−1a on hospitalized patients with COVID‐19: SBMU Taskforce on the COVIFERON study

Fallahzadeh, Mohammad Hossein; Pourhoseingholi, Mohamad Amin; Boroujeni, Masoud Ghanbari; Besharati, Sajad; Mardani, Masoud; Shabani, Minoosh; Shokouhi, Shervin; Amirdosara, Mahdi; Hajiesmaeili, Mohammadreza; Gachkar, Latif; Roshan, Baran; Zangi, Mahdi; Mirmomeni, Golshan; Irvani, Seyed Sina Naghibi; Darazam, Ilad Alavi

doi:10.1002/jmv.27475

Cited by 6 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interferons (IFNs) are fundamental agents of the innate immune system, thanks to their action against viruses and their immunomodulatory functions [ 58 ]. IFN-β, used as a treatment for hospitalized patients who are COVID-19 positive, has been demonstrated to have significant efficacy, as it may diminish the hospitalization time, the ICU admission rate, the need for invasive respiratory support and the mortality rate of patients with severe COVID-19 [ 58 , 59 ]. Despite this, there are a few individual cases that report the onset of AP due to IFN, and for that reason, it is included in Class III of the Badalov classification of drugs [ 12 , 25 ].…”

Section: Discussionmentioning

confidence: 99%

Drug-Induced Acute Pancreatitis in Hospitalized COVID-19 Patients

et al. 2023

View full text Add to dashboard Cite

Coronavirus disease-19 (COVID-19), caused by SARS-CoV-2, is a systemic disease that affects not only the respiratory system, but also other systems, including gastrointestinal. A great number of different drugs have been used on hospitalized patients for the management of COVID-19, and acute pancreatitis (AP) has been reported as a complication or side effect of these drugs. The development of drug-induced acute pancreatitis (DIAP) follows a complex of pathophysiological mechanisms, and particular risk factors play a key role. Diagnosis of DIAP depends on specific criteria, and based on these, a drug may be characterized as having a definite, probable or possible connection with AP. The aim of this review is to present the medications that are used for COVID-19 management and are associated with AP in hospitalized patients. The list of these drugs mainly includes corticosteroids, glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), antiviral agents, antibiotics, monoclonal antibodies, estrogens and anesthetic agents. Moreover, the prevention of the development of DIAP is vital, especially for critically ill patients who may receive multiple drugs. DIAP management is mainly non-invasive and the first step concerns the exception of the suspicious drug from patients therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug-Induced Acute Pancreatitis in Hospitalized COVID-19 Patients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Interferon beta1-a (IFN-β1a) demonstrated considerable efficacy in COVID-19 patients in a recent clinical trial. Previous in vitro studies demonstrated interferon-β antiviral efficacy against the SARS virus (Fallahzadeh et al 2022 ). Both types of IFNs may cause diabetes mellitus because it has been documented that long-term therapeutic use of type I IFNs causes autoimmunity as well as the emergence of type 1 diabetes after treatment with type I IFNs (Pelegrin et al 1998 ).…”

Section: Association Between Covid-19 Treatment Drugs and Diabetesmentioning

confidence: 99%

Diabetes as one of the long-term COVID-19 complications: from the potential reason of more diabetic patients’ susceptibility to COVID-19 to the possible caution of future global diabetes tsunami

et al. 2023

View full text Add to dashboard Cite

According to recent researches, people with diabetes mellitus (type 1 and 2) have a higher incidence of coronavirus disease 2019 (COVID-19), which is caused by a SARS-CoV-2 infection. In this regard, COVID-19 may make diabetic patients more sensitive to hyperglycemia by modifying the immunological and inflammatory responses and increasing reactive oxygen species (ROS) predisposing the patients to severe COVID-19 and potentially lethal results. Actually, in addition to COVID-19, diabetic patients have been demonstrated to have abnormally high levels of inflammatory cytokines, increased virus entrance, and decreased immune response. On the other hand, during the severe stage of COVID-19, the SARS-CoV-2-infected patients have lymphopenia and inflammatory cytokine storms that cause damage to several body organs such as β cells of the pancreas which may make them as future diabetic candidates. In this line, the nuclear factor kappa B (NF-κB) pathway, which is activated by a number of mediators, plays a substantial part in cytokine storms through various pathways. In this pathway, some polymorphisms also make the individuals more competent to diabetes via infection with SARS-CoV-2. On the other hand, during hospitalization of SARS-CoV-2-infected patients, the use of some drugs may unintentionally lead to diabetes in the future via increasing inflammation and stress oxidative. Thus, in this review, we will first explain why diabetic patients are more susceptible to COVID-19. Second, we will warn about a future global diabetes tsunami via the SARS-CoV-2 as one of its long-term complications.

show abstract

Study of the effects of interferon β−1a on hospitalized patients with COVID‐19: SBMU Taskforce on the COVIFERON study

Fallahzadeh

Pourhoseingholi

Boroujeni

et al. 2021

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Interferons are an essential part of the innate immune system and have antiviral and immunomodulatory functions. We studied the effects of interferon β‐1a on the outcomes of severe cases of coronavirus disease 2019 (COVID‐19). This retrospective study was conducted on hospitalized COVID‐19 patients in Loghman‐Hakim hospital from February 20, 2020 to April 20, 2020, Tehran, Iran. Patients were selected from two groups, the first group received interferon β‐1a in addition to the standard treatment regimen, and the second group received standard care. The clinical progression of two groups during their hospital admission was compared. We studied a total number of 395 hospitalized COVID‐19 patients. Out of this number, 111 patients (33.5%) died (31.3% of the interferon β‐1a group and 34.1% of the control group). The mortality rate indicated no statistically significant difference between groups (p‐value = 0.348), however for patients who were hospitalized for more than a week, the rate of mortality was lower in the interferon β‐1a group (p‐value = 0.014). The median hospital stay was statistically longer for patients treated by interferon β‐1a (p‐value < 0.001). The results of this study showed that interferon β‐1a can improve the outcomes of hospitalized patients with severe COVID‐19, but more adequately‐powered randomized controlled trials should be conducted.

show abstract

Study of the effects of interferon β−1a on hospitalized patients with COVID‐19: SBMU Taskforce on the COVIFERON study

Cited by 6 publications

References 29 publications

Drug-Induced Acute Pancreatitis in Hospitalized COVID-19 Patients

Drug-Induced Acute Pancreatitis in Hospitalized COVID-19 Patients

Diabetes as one of the long-term COVID-19 complications: from the potential reason of more diabetic patients’ susceptibility to COVID-19 to the possible caution of future global diabetes tsunami

Study of the effects of interferon β−1a on hospitalized patients with COVID‐19: SBMU Taskforce on the COVIFERON study

Contact Info

Product

Resources

About